SCHEDULE: General Atlantic Adjusts Pharvaris Stake to 7.6%

General Atlantic entities have collectively adjusted their beneficial ownership of Pharvaris N.V. ordinary shares to 7.6%, as reported in an amended Schedule 13G filing.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Pharvaris N.V. ordinary shares.
• The reporting entities, collectively referred to as 'Reporting Persons' and including various General Atlantic entities, now beneficially own 5,359,727 ordinary shares.
• This represents 7.6% of the issued and outstanding ordinary shares of Pharvaris N.V.
• The outstanding shares are based on the Company's Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership percentage without providing new operational or financial performance data.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing reflects a significant institutional investor's stake in a publicly traded company, a common occurrence in the biotechnology or pharmaceutical sectors where Pharvaris N.V. operates. Changes in beneficial ownership by large investment firms often signal ongoing confidence or strategic adjustments.

Stakeholder Impact

• Shareholders: The adjustment in beneficial ownership by a major investor like General Atlantic may influence market perception and potentially trading activity.

Key Dates

Keywords

Pharvaris N.V., General Atlantic, Beneficial Ownership, Schedule 13G, Ordinary Shares, Investment Management